Karyopharm Therapeutics | KPTI - Net Income


Karyopharm Therapeutics reported $-22.39M in Net Income for its fiscal quarter ending in March of 2026.





Net Income Change Date
AbbVie USD 3.61B 2.92B Jun/2026
Abbott USD 928M 149M Jun/2026
Amgen USD 2.38B 556M Jun/2026
AstraZeneca USD 2.51B 573M Jun/2026
BioCryst Pharmaceuticals USD 78.4M 167.45M Jun/2026
Bristol-Myers Squibb USD 3.32B 640M Jun/2026
Eli Lilly USD 7.1B 301M Jun/2026
Enanta Pharmaceuticals USD -22.29M 93.76M Dec/2024
GlaxoSmithKline GBP 435M 1.3B Jun/2026
Incyte USD 585.6M 282.27M Jun/2026
J&J USD 210M 5.32B Sep/2026
Karyopharm Therapeutics USD -22.39M 79.81M Mar/2026
MacroGenics USD -36.77M 22.62M Mar/2026
Merck USD -1.34B 2.9B Jun/2026
Nektar Therapeutics USD -44.9M 8.82M Mar/2026
Novartis USD 3.26B 108M Jun/2026
Novartis USD 3.16B 747M Mar/2026
Pfizer USD -248M 2.94B Jun/2026
Regeneron Pharmaceuticals USD 1.3B 569.7M Jun/2026
Roche Holding CHF 6.87B 1.4B Jun/2026
Sangamo BioSciences USD -36.13M 12.96M Jun/2024
Takeda JPY 113.2B 137.52B Jun/2026
Tectonic Therapeutic USD -25.24M 6.02M Mar/2026
TG Therapeutics USD 7.78M 12M Jun/2026
Ultragenyx Pharmaceutical USD -185M 56M Mar/2026
Xencor USD -21.73M 107.19M Jun/2026